Riamilovir

Triazavirin is a guanine nucleotide analog antiviral first developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications. Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19. Its therapeutic use is listed as antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Triazavirin, 7-(methylsulfanyl)-3-nitro-1H, 4H-(1, 2, 4)triazolo(3, 2-c)(1, 2 and 4)triazin-4-one. Its PubChem CID is 3113817.

CAS No 123606-06-4
Molecular Formula C5H4N6O3S
Molecular Weight 228.19 g/mol
Synonyms 7-methylsulfanyl-3-nitro-6H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one

Frequently Asked Questions